文献速递免疫规划慢病防控与筛查卫生政策与健康促进

美国18-49岁重症RSV高风险成人接种佐剂RSVPreF3疫苗的公共卫生影响与成本效果

Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.
PubMed 文献 · Vaccine · 2026-06-25

本研究采用静态多队列马尔可夫模型,模拟美国18-49岁重症RSV高风险成人接种佐剂RSVPreF3疫苗与不接种相比5年内的公共卫生影响和成本效果,假设接种率与流感疫苗相同。结果估计可避免869,819例RSV病例、303,924例RSV相关门诊就诊、444例RSV相关死亡和20,540个QALY损失,社会视角ICER为每获得1个QALY 61,717美元。结论提示该人群接种具有可观公共卫生获益和成本效果。

要点

  • 模型估计5年内可避免869,819例RSV病例和444例RSV相关死亡。
  • 社会视角ICER为每QALY 61,717美元。
  • 在所有特定疾病亚组中,按假设支付阈值15万美元/QALY,接种具有成本节约或成本效果。

核心结论

  • 模型结果表明,美国18-49岁重症RSV高风险成人接种佐剂RSVPreF3疫苗具有可观的公共卫生获益和成本效果。

研究设计与样本

  • 采用静态多队列马尔可夫模型,模拟接种佐剂RSVPreF3疫苗与不接种相比5年内的公共卫生影响和成本效果,假设接种率与流感疫苗相同。
  • 基础病例人群为18-49岁、具有至少1项重症RSV危险因素(哮喘、冠心病、心力衰竭、慢性肾病、糖尿病和/或重度肥胖)的成人。
  • 模型输入基于现有文献;基础病例分析从社会视角(直接和间接成本)估计增量RSV病例、RSV相关医疗资源使用和死亡、贴现的质量调整生命年(QALY)损失及增量成本效果比(ICER)。
  • 敏感性分析评估模型输入变化和参数不确定性;情景分析从医疗部门视角(仅直接成本)及特定疾病亚组估计ICER。

主要发现

  • 在24,260,162名18-49岁高风险成人中,7,957,333人接种佐剂RSVPreF3疫苗,估计5年内可避免869,819例RSV病例。
  • 上述接种估计可避免303,924例RSV相关门诊就诊、444例RSV相关死亡和20,540个QALY损失。
  • 社会视角对应的ICER为每获得1个QALY 61,717美元。
  • 情景分析估计,基于假设的每QALY 150,000美元支付阈值,佐剂RSVPreF3疫苗接种在所有特定疾病亚组中具有成本节约或成本效果。
  • 结果在敏感性分析中保持稳健。

关键数值与推荐

  • 基础病例人群定义为18-49岁、具有至少1项重症RSV危险因素(哮喘、冠心病、心力衰竭、慢性肾病、糖尿病和/或重度肥胖)的成人。
  • 社会视角ICER为每QALY 61,717美元。
  • 情景分析采用假设支付阈值每QALY 150,000美元。

临床怎么用

  • 可为18-49岁具有哮喘、冠心病、心力衰竭、慢性肾病、糖尿病和/或重度肥胖等重症RSV危险因素的成人接种佐剂RSVPreF3疫苗提供成本效果依据。
  • 接种策略可参考流感疫苗的接种率假设进行规划。
  • 决策时可结合社会视角ICER与假设支付阈值评估经济性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adults with certain medical conditions (e.g., chronic pulmonary or cardiovascular disease, weakened immune systems) are at increased risk for severe respiratory syncytial virus (RSV) disease, which can have substantial clinical and economic burden. This study evaluated the public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among United States (US) adults aged 18-49 years at increased risk for severe RSV disease. METHODS: A static, multicohort Markov model simulated adjuvanted RSVPreF3 vaccination versus no vaccination over 5 years, assuming the same uptake as influenza vaccines. The base-case population included adults aged 18-49 years with ≥1 of the following risk factors for severe RSV disease: asthma, coronary artery disease, heart failure, chronic kidney disease, diabetes, and/or severe obesity. Model inputs were informed by existing literature. The base-case analysis estimated incremental RSV cases, RSV-related healthcare resource use and deaths, discounted quality-adjusted life years (QALYs) lost, and incremental cost-effectiveness ratios (ICERs) from a societal perspective (direct and indirect costs). Sensitivity analyses assessed varying model inputs and parameter uncertainty, while scenario analyses estimated ICERs from a healthcare sector perspective (direct costs only) and among condition-specific subgroups. RESULTS: Overall, 7,957,333 of the total 24,260,162 increased-risk adults aged 18-49 years received adjuvanted RSVPreF3 vaccination, which was estimated to avoid 869,819 RSV cases over 5 years, including 303,924 RSV-related outpatient visits, 444 RSV-related deaths, and 20,540 QALY losses versus no vaccination. The corresponding ICER was $61,717 per QALY gained from the societal perspective. Scenario analyses estimated that adjuvanted RSVPreF3 vaccination was cost-saving or cost-effective among all condition-specific subgroups based on a hypothetical willingness-to-pay threshold of $150,000 per QALY gained. Results were robust across sensitivity analyses. CONCLUSIONS: Model findings suggest considerable potential public health benefits and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Singer D, La EM, Dubois de Gennes C, et al. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease. Vaccine. 2026. PMID: 42349134. doi:10.1016/j.vaccine.2026.128770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。